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INTRODUCTION 
Interleukin-10 (IL-10) is an anti-inflammatory cytokine, 
which active form is a non-covalent homodimer with 
two intramolecular disulphide bonds that are essential to 
its biological activity, which includes reduction of 
tumor necrosis factor α (TNF-α) synthesis and down-
regulation of class II major histocompatibility complex 
(MCH-II) molecules on monocytes/macrophages (de 
Waal Malefyt, 1991). Due to IL-10 potential 
applications in various medical fields, it is essential to 
develop systems that can effectively deliver the protein. 
A promising system is protein encapsulation by 
polymeric nanopartices (NPs), which minimize 
denaturation, and enables slow-release, while 
maintaining an effective concentration for the necessary 
period of time. In previous work, we have developed 
and characterized NPs obtained by self-assembling of 
hydrophobized dextrin (Gonçalves, 2007) whose 
properties makes them promising for IL-10 delivery.  
METHODS 
The recombinant mutated (C149Y) murine IL-10 (rIL-
10) was expressed, in form of inclusion bodies, in E. 
coli BL21 star. rIL-10 was recovered by a process of 
solubilization in 6M guanidine, renaturation and re-
oxidation of disulphides. The dimeric form of rIL-10 
was collected by gel filtration and further purified by 
ion-exchange chromatography. SDS-PAGE analysis 
was used to confirm molecular weight and purity. The 
amount of rIL-10 obtained was quantified by ELISA. 
rIL-10 bioactivity was assayed by its ability to inhibit 
the production of TNF-α, quantified by ELISA, and the 
surface expression of MHC-II molecules, monitorized 
by FACS analysis, in lipopolysacharide (LPS) and IFN-
γ activated bone marrow derived macrophages 
(BMDM). 
To form the self-assembled NPs, lyophilized dextrin-
VMA-SC16 was resuspended in culture medium, at 
room temperature. NPs formation was confirmed by 
dynamic light scattering. The complex NPs/rIL-10 was 
formed by dissolving rIL-10 in culture medium and then 
by mixing lyophilized dextrin-VMA-SC16. rIL-10 
incorporation into NPs was verified quantifying the 
amount of rIL-10 free in solution by ELISA. The IL-10 
stability was accessed by circular dichroism (CD). The 
release of rIL-10 from the complex NPs/rIL-10 was 
assessed in a BMDM culture, by measuring free rIL-10 
by ELISA. Bioactivity of rIL-10 released from the 
NPs/rIL-10 complex was assayed as described 
previously. 
RESULTS  
SDS-PAGE confirmed the expression and molecular 
weight (18 kDa) of the rIL-10 as well as their purity. 
Total recovery of dimeric rIL-10 was about 1-1.5 mg/L 
culture, quantified by ELISA. 
rIL-10 (in the range of 0.1 to 250 ng/mL) shown the 
ability to inhibit the TNF-α production and to reduce 
MHC-II expression on stimulated BMDM (figure 1A 
and B). 
 
Figure 1: Biological activity of rIL-10 and cIL-10. (A) 
Percentage of inhibition of TNF-α production, by 0.1 
ng/ml LPS and 1.0 ng/ml INF-γ stimulated BMDM. (B) 
Percentage of MHC-II expression induced by cIL-10 
and rIL-10 treatment of stimulated BMDM. Data points 
are the means ± SD. (+) – positive control of 
macrophage activation; (-) – negative control of 
macrophage activation. 
rIL-10 incorporation by NPs was confirmed by 
quantifying, the amount of rIL-10 in free in solution, 
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that was negligible. The secondary structure of free 
soluble rIL-10 is mainly helical (Zdanov, 1995), and the 
complexation in the nanogel did not induce any 
conformational change (figure 2). Further CD studies 
showed that rIL-10 stability is significantly increased 
when it is complexed with the dextrin nanogel. 
 
Figure 2: CD spectra of free rIL-10 (0.25 mg/ml) and 
complex nanogel/rIL-10 (1 mg/ml nanogel and 0.25 
mg/ml rIL-10) at 37ºC in PBS. 
In the presence of 20% serum, rIL-10 is being released 
over time in a BMDM culture. After two hours of 
incubation with the NPs/rIL-10 complex, the rIL-10 
reaches a maximum concentration; a stable value of 
about 35 ng/mL rIL-10 being estimated after twenty-
four hours.  
 
Figure 3:Biological activity of rIL-10 released from 
nanogel/rIL-10 complex. (A) TNF-α concentration 
(pg/ml), produced by 0.1 ng/ml LPS and 1.0 ng/ml INF-
γ stimulated BMDM, treated with rIL-10 and 
nanogel/rIL-10. (B) MHC-II induced, in stimulated 
BMDM, by 50 ng/ml rIL-10 and nanogelrIL-10. Data 
points are the means±SD. (+) – positive control of 
macrophage activation; (-) – negative control of 
macrophage activation. 
The rIL-10 released from the NPs/rIL-10 complex was 
able to inhibit TNF-α production and MHC-II 
expression at the same level as the soluble rIL-10 
(figure 3A and B). 
DISCUSSION & CONCLUSIONS 
A mutated form of murine IL-10 was successfully 
expressed in E. coli. This recombinant protein was 
recovered and purified from inclusion bodies and 
demonstrated biological activity similar to a 
commercially available IL-10. Dextrin self-assembled 
nanogel was able to efficiently encapsulate and protect 
rIL-10 from denaturation at 37ºC, and also enables rIL-
10 to be released in biologically significant amounts 
over time. The biological activity of the released rIL-10 
was confirmed by the evaluation of the production of 
TNF-α and expression of MHC-II on endotoxin-
stimulated BMDM. The simplicity of the preparation of 
the nanogel/rIL-10 complex, associated to the 
enhancement of protein stability and controlled release, 
makes this a very promising system. 
IL-10 has potential application in various medical fields, 
such as in acute inflammatory diseases, namely 
rheumatoid arthritis, and these results point to dextrin 
nanogel as a promising carrier of IL-10, which enables 
the protein sustained release.  
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